Background: Multiple sclerosis is an autoimmune chronic inflammatory disease of the
central nervous system that can lead to some serious disabilities. Despite using various immunomodulatory
and anti-inflammatory drugs that have therapeutic effects, they cannot reduce its progression
completely and have some unwanted side effects too. The immunomodulatory and anti-inflammatory
effects of the β-D-Mannuronic acid (M2000) have been proven in several surveys, and the
present research was designed to determine its toxicity and therapeutic effects in MS patients.
Methods: This study was performed on 15 MS patients who took 25 mg/kg/day the oral form of
the β-D-Mannuronic acid for six months, and 15 healthy people as a control group. Serum levels of
Urea, Creatinine, GGT, Vitamin D3, Uric acid, and Anti-Phospholipids were compared to evaluate
the therapeutic and possible toxic effects of this drug after this period.
Results: Non- toxic effects through the study of urea, creatinine, GGT, and non-significant changes
in uric acid and anti-Phospholipids levels, besides a significant rise in vitamin, D3 levels in the
M2000 treated cases were found.
Conclusions: Our results suggested that β-D-Mannuronic acid is a safe drug and has no toxicity
when administered orally and also has some therapeutic effects in MS patients.